Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
Journal of Breast Cancer ; : 141-148, 2019.
Artigo em Inglês | WPRIM | ID: wpr-738408

RESUMO

The luteinizing hormone-releasing hormone/androgen receptor (LHRH/AR) pathway is a promising treatment target in a subgroup of female patients with triple-negative breast cancer (TNBC). However, very little is known about the efficacy of this strategy in male patients with TNBC. In this report, we describe a male patient with AR-positive TNBC who was successfully treated using an LHRH agonist after pretreatment with several lines of chemotherapy and achieved a durable response. We also review the existing evidence supporting LHRH- and AR-targeted therapy for this rare disease.


Assuntos
Feminino , Humanos , Masculino , Masculino , Neoplasias da Mama Masculina , Tratamento Farmacológico , Hormônio Liberador de Gonadotropina , Gosserrelina , Luteína , Doenças Raras , Receptores Androgênicos , Neoplasias de Mama Triplo Negativas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA